Simple research view

MRNA · Moderna, Inc.

$58.07 latest stored close

Detected setup Trend Only

Watch · Quality 72/100

Ask about MRNA

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$MRNA

Moderna, Inc.

Moderna, Inc. is a large-cap Biotechnology company in the Health Technology sector with a market cap of $23B.

Buy · 69 Health Technology Biotechnology stock Stage 2 · Advancing Base 4+ Data 59m ago

$58.07 latest close

← Back Join to Watchlist $MRNA Share card

Council read · 6 methods

Watch — evidence is building

0 buyable · 5 watch · 1 avoid. Review the observed passes and blockers before reading the chart.

Review six verdicts Inspect chart

Earnings-risk mode

Pre-earnings setup

Friday, July 31, 2026 Time not confirmed No sourced report session or clock time

Ordinary position sizing suppressed. Earnings are less than three full trading sessions away; treat the gap as event risk, not ordinary stop-distance risk.

Deterministic evidence

MRNA-2.67%

Sector proxy · XLV-0.51%

Broad market · SPY-0.12%

Same completed session window ending 2026-07-22. MRNA was -2.16 points vs XLV. -2.55 points vs SPY.

CatalystUnavailable Stock reactionNegative Sector reactionWeak Opening surgeUnavailable Event riskEarnings-driven

Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

AI interpretation (optional)

Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.

Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.

Price $58.07 Jul 22 close

52W High $85.60 -32.2%

52W Low $22.28

Wks Since High 2w

Base Depth -32.5%

Base B4

SMA 50 $57.60

SMA 200 $43.87

Avg Vol 7,852,949

RS Rank 90

RS vs High -28.6%

RS Slope -5.7% ▼

Grp Rank #36/64

ADR% 6.6%

ATR(14) $4.70 (8.1%)

Rel Vol (today) 0.48×

Vol Pace N/A

U/D Vol 1.85

A/D Days 11A / 8D

A/D Rating A

VDU Bars 0/10 d

Earnings 3d

$22.28

$85.60 57%

MRNA Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for MRNA.

Create Free Account

Setup Quality C 3/7 signals

Score trend

✓ Stage 2 · Advancing ✗ Power Trend ✗ RS New High ✓ Trend 7/8 ✗ No Pattern ✓ Gatekeeper Base #4 (C)

See the full conviction stack.

Unlock Insights

Technical Analysis Report Card

$MRNA · $58.07 · as of 2026-07-22 · multi-factor read

/ 100

Buy

Trend · Daily / Weekly / Monthly

Daily ▬ Sideways / consolidating

Weekly ▬ Sideways / consolidating

Monthly ▬ Sideways / consolidating

Moving Averages

50-day$57.60 ↑

100-day$54.60 ↑

200-day$43.87 ↑

Bullish (50 > 200)

RSI (14)

Reading41.5 · Bearish

Bearish momentum — sellers in control.

MACD (12/26/9)

StateWeakening

Histogram-2.373

Weakening — MACD slipped below its signal line. Histogram contracting.

Bollinger Bands (20,2)

%B / Width16% · 43.2%

Near the lower band — under pressure or oversold.

Volume · Buyer vs Seller

Up/Down vol1.85 · Accumulation

Rel volume0.48×

Accumulation — volume is concentrated on up days; buyers dominate. Recent volume is easing versus its baseline.

Support & Resistance

R · $59.52swing level

R · $85.6052-week high

Price · $58.07now

S · $48.09swing level

S · $47.14swing level

S · $45.62swing level

Fibonacci · Uptrend swing

23.6%$74.05

38.2%$66.90

50.0%$61.12

61.8%$55.35

78.6%$47.13

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.

Unlock the exact entry, stop-loss, profit target, and reward-to-risk for MRNA — plus the full 495-symbol scanner and Ask-the-Legends chat.

🔒 Start your 7-day free trial →

Above 200-day MA50/200 bullishVolume accumulationRS 87 (leader)5.9:1 reward-to-risk

Want this read in a legend's voice? 💬 Ask a Legend about MRNA

Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →

Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 🟡 5 of 6 legends are Watching — building, not yet a confirmed buy.

Minervini

Watch

Minervini C

Trend-template read: 6/10 pass; wait for the soft misses to improve.

Passing evidence

1.1 Price > 150-day MA AND 200-day MAPrice $58.07, MA150 $49.79, MA200 $43.87

1.2 150-day MA > 200-day MAMA150 $49.79 vs MA200 $43.87

Failing evidence

1.7 Price within 25% of 52-week high32.2% below 52-week high

2. Quarterly EPS growth ≥ 25%From SEPA scan

6/10 checks

Method → Playbook → Ask →

O'Neil

Avoid

O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence

L: RS rank ≥ 80 (IBD leadership)RS rank 87

Failing evidence

C: Quarterly EPS acceleration ≥ 25%Data unavailable

A: Annual earnings & revenue qualityRev -39.9%

1/8 checks

Method → Playbook → Ask →

Weinstein

Watch

Weinstein C

Stage-analysis read: Stage 2 is present; 3 supporting checks need improvement.

Passing evidence

Stage 2 (Advancing phase) confirmedStage 2 (Advancing)

Price above 30-week MA (200-day proxy)Price $58.07 vs MA200 $43.87

Failing evidence

Volume expansion above averageVolume ratio 0.48x

Not extended from 52-week high (≤ 30% below)32.2% below 52-week high

4/7 checks

Method → Playbook → Ask →

Livermore

Watch

Livermore B

Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence

Price$58.07

Relative strengthRS 87

Failing evidence

Volume vs average0.48x

Distance from 52-week high32.2% below high

3/6 checks

Method → Playbook → Ask →

Darvas

Watch

Darvas B

Box-theory read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence

Price$58.07

Relative strengthRS 87

Failing evidence

Volume vs average0.48x

Distance from 52-week high32.2% below high

3/6 checks

Method → Playbook → Ask →

Wyckoff

Watch

Wyckoff B

Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence

Price$58.07

Relative strengthRS 87

Failing evidence

Volume vs average0.48x

Distance from 52-week high32.2% below high

3/6 checks

Method → Playbook → Ask →

Breakout Health

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

Unlock Follow-Through Tracking

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▼ Falling

Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net -4 A

Minervini · Grade Card

Fundamentals & leadership quality — Minervini SEPA criteria · 2/7 met

C 2/7 SEPA

Separate score from the 8-point Trend Template (7/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.

✗ EPS acceleration ≥25% QoQ —

✗ Revenue growth ≥20% YoY -40%

✗ Gross margin ≥30% —

✗ ROE ≥17% —

✓ RS rating ≥80 (leadership) 87

✓ Stage 2 uptrend (Weinstein) Stage 2

✗ Within 25% of 52W high -32.2%

Method Playbook

📋 Trade it like Minervini EXACT LEVELS · PRO

Minervini O'Neil Livermore Weinstein Darvas Wyckoff

Minervini C · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.

Pivot

Pro level

Published-method rule: Use the tight base's structural pivot; the setup must retain Trend Template leadership into the trigger.
Evidence: Canonical setup geometry is available with Pro.

Entry trigger

Pro level

Published-method rule: Require a decisive move through the pivot with volume confirmation, and do not initiate more than 5% above it.
Evidence: Canonical setup geometry is available with Pro.

Initial stop

Pro level

Published-method rule: Start at the tighter structural invalidation; the initial loss limit must not exceed roughly 7–8% from entry.
Evidence: Canonical setup geometry is available with Pro.

Trail

Rule-based

Published-method rule: Hold the initial stop until the trade proves itself; near +1R move to breakeven, then trail a higher low or rising 10/21-day average once well extended.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.

Exit / invalidation

Pro level

Published-method rule: Exit when the structural stop or a meaningful higher-low/short-term trend violation fires; never widen the stop.
Evidence: Canonical setup geometry is available with Pro.

Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis (historical · 5d ago)

Trend Only

72.0 score

RS Score 87

Trend 7/8 ✓

Why This Setup?

Trend Only

The Universal Edge Check

The panel is uneasy

Too many universals unmet — this leans closer to a guess than a trade.

2/7 universals met

In a confirmed uptrend Stage 2 · Trend 7/8
Risk is defined No stop — undefined risk
Asymmetric reward No target set
Not chasing (in range) Pivot distance unknown
Volume confirms 0.5× average — light
Clear of earnings in 3 days — event risk
A relative-strength leader RS 90

Why these seven? → The Universal Edge

Minervini Trend Template

7/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $58.07 vs SMA150 $49.79 / SMA200 $43.87

SMA 150 above SMA 200 SMA150 $49.79 vs SMA200 $43.87

SMA 200 trending up Slope +4.29 over 20 days

SMA 50 above SMA 150 & 200 SMA50 $57.60

Price above SMA 50 $58.07 vs SMA50 $57.60

30%+ above 52W low +160.6% from $22.28

Within 25% of 52W high -32.2% from $85.60

RS score above 70 RS 87

Fundamentals

52W Range

57%

Mkt Cap SEC

23.0B

Rev YoY

-40%

EPS TTM

$-7.26

Float

397M

Insider

No Buy

Company

Legend AI snapshot

Moderna, Inc.

MRNA · NASDAQ · Health Technology · Biotechnology

$58.07latest close $23.0Bmarket cap 90RS rank 72setup score

Weekly Context

Multi-timeframe signals from weekly bars

W. Trend

7/8

W. RS

100

W. Support

$36.65

W. Resist

$85.60

Weekly Structure

Trend Neutral

Tight Weeks 0

Confirmation Neutral

Scan History

Jul 23

Trend Only ✓ Gate

Jul 22

Trend Only ✓ Gate

76 0.0%

Jul 22

Trend Only ✓ Gate

74 0.0%

Jul 22

Trend Only ✓ Gate

74 0.0%

Jul 21

Trend Only ✓ Gate

73 -2.7%

Jul 21

Trend Only ✓ Gate

72 -2.7%

Get the full picture on MRNA

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.

Start 7-Day Free Trial